At the news
? NEUTRALIMPACT 2/10 8-K filed Jun 16, 2026 at 16:34 ET
Travere Therapeutics disclosed the planned retirement of Chief Research Officer William Rote, effective February 17, 2027, with an orderly transition to Jula Inrig, who becomes EVP, Head of R&D and CMO effective July 1, 2026. This is a routine executive succession with long notice and a named internal successor, carrying no immediate financial or operational implications.
- Chief Research Officer William Rote, Ph.D., notified the company of his retirement effective February 17, 2027, the 10-year anniversary of his employment.
- Dr. Rote will continue in his current role through the retirement date and assist in the transition.
- Jula Inrig, M.D., current Chief Medical Officer, will assume Dr. Rote's responsibilities and be named Executive Vice President, Head of Research & Development and Chief Medical Officer effective July 1, 2026.
- The company expects to enter into a consulting arrangement with Dr. Rote post-retirement.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access